SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Trillium Therapeutics
TRIL 20.36+2.0%Nov 26 2:56 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
Recommended by:
ghmm
From: Biomaven2/3/2018 7:15:18 PM
1 Recommendation  Read Replies (2) of 294
 
So dramatic expansion in the size and scope of the intratumoral trials. I really don't think they would do this unless they'd seen something of note (like some abscopal effects) and there was investigator enthusiasm. Going to have to expand the number of sites too I would think.

Might be you really do need to get to close to 100% receptor occupancy to really liven-up the immune system. There was one CD47 publication I read a while back that hinted at that, although the company has always claimed in preclinical experiments that moderate occupancy was all you needed.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News